Avalyn Pharma Inc.
AVLN
$38.74
$2.165.91%
NASDAQ
| 06/30/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 30.70% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 12.11% | ||||
| Operating Income | -12.11% | ||||
| Income Before Tax | -7.69% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -7.69% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -7.69% | ||||
| EBIT | -12.11% | ||||
| EBITDA | -11.97% | ||||
| EPS Basic | 95.53% | ||||
| Normalized Basic EPS | 95.53% | ||||
| EPS Diluted | 95.53% | ||||
| Normalized Diluted EPS | 95.53% | ||||
| Average Basic Shares Outstanding | 2,309.25% | ||||
| Average Diluted Shares Outstanding | 2,309.25% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||